Maximising secondary prevention therapies in patients with coronary heart disease

Heart

Volumn 94, Issue 1, 2008, Pages 8-9

  Capewell, S ^a   O'Flaherty, M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIET; EDITORIAL; EXERCISE; HEALTH BEHAVIOR; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LIFESTYLE; MEDICAL DECISION MAKING; MORTALITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK REDUCTION; SECONDARY PREVENTION; SMOKING CESSATION; SURVIVAL RATE;

CORONARY DISEASE; DELIVERY OF HEALTH CARE; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HUMANS; MALE;

EID: 37749003775     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.123125     Document Type: Editorial

References (20)

1. SIGN. Risk estimation and prevention of cardiovascular disease. A national guideline. Clinical Guidelines 2007. Available at http://www.sign.ac.uk/ pdf/sign97.pdf (accessed 24 October 2007).
2. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. NEJM 2007;356:2388-98.
3. Unal B, Critchley J, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales, 1981-2000. Circulation 2004;109:1101-7.
4. Fidan D, Unal B, Critchley J, et al. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010. QJM 2007;100:277-89.
5. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
6. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997;18:1569-82.
7. DeWilde S, Carey IM, Richards N, et al. Trends in secondary prevention of ischaemic heart disease in the UK 1994-2005: use of individual and combination treatment. Heart 2008;94:83-8.
8. Capewell S, Murphy NF, MacIntyre K, et al. Short-term and long-term outcomes in 133 429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990-2000: population-based cohort study. Heart 2006;92:1563-70.
9. Capewell S, Unal B, Critchley JA, et al. Over 20,000 avoidable coronary deaths in England and Wales in 2000: the failure to give effective treatments to many eligible patients. Heart 2006;92:521-3.
10. Ashworth M, Lloyd D, Smith RS, et al. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. J Public Health (Oxf) 2007;29:40-7.
11. Packham C, Robinson J, Morris J, et al. Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med 1999;21:60-4.
12. Strong M, Maheswaran R, Radford J. Socioeconomic deprivation, coronary heart disease prevalence and quality of care: a practice-level analysis in Rotherham using data from the new UK general practitioner Quality and Outcomes Framework. J Public Health 2006;28:39-42.
13. Macintyre K, Stewart S, Chalmers J, et al. Relation between socioeconomic deprivation and death from a first myocardial infarction in Scotland: population based analysis. BMJ 2001;322:1152-3.
14. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
15. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3.
16. Summerskill WSM, Pope C. 'I saw the panic rise in her eyes, and evidence-based medicine went out of the door.' An exploratory qualitative study of the barriers to secondary prevention in the management of coronary heart disease. Fam Pract 2002;19:605-10.
17. Biondi-Zoccai GGL, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667-74.
18. Shepherd J, Alcalde V, Béfort PA, et al. International comparison of awareness and attitudes towards coronary risk factor reduction: the HELP study. Heart European Leaders Panel. J Cardiovasc Risk 1997;4:373-84.
19. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Archiv Intern Med 2005;165:1147-52.
20. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113:203-12.